Sweet surprise: dates may improve blood sugar in diabetes trial
NCT ID NCT07467967
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether eating 3 dates daily for 8 weeks can improve blood sugar control and reduce oxidative stress in 130 adults with well-controlled type 2 diabetes. Participants replace a carbohydrate portion with dates to keep calories steady. The goal is to see if this simple dietary change is safe and potentially beneficial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dates (Deglet Nour variety)
- What this could lead to
- If it works, this could show that moderate date consumption is safe and may help improve blood sugar control and reduce oxidative stress in type 2 diabetes.
- What could go wrong
- This is a small, early-stage study with only 130 participants over 8 weeks. Results may not apply to all diabetes patients, and dates are high in sugar, which could raise blood sugar if not carefully substituted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 130 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-65 years * Type 2 diabetes diagnosed for at least one year * Well-controlled diabetes on oral antidiabetic drugs for at least 3 months, with a target baseline HbA1c \< 8% * Duration of diabetes \< 15 years * Patient available for an 8-week period * Written informed consent Non-inclusion Criteria: * Patients on insulin therapy * Oral antidiabetic treatment modified within the 3 months prior to inclusion * Diabetes with established microvascular or macrovascular complications * Severe intercurrent diseases (severe renal insufficiency, severe liver disease, cardiovascular history, neoplasia, inflammatory disease) * Pregnancy or breastfeeding * Known allergy or intolerance to dates * Dietary regimens incompatible with isocaloric substitution (e.g., strict ketogenic diet, prolonged fasting) * Inability to understand or comply with study instructions (cognitive impairment, language barrier without interpreter, major logistical constraints) Exclusion Criteria: * Initiation of insulin therapy or major modification of antidiabetic treatment * Occurrence of pregnancy during the study * Development of a serious adverse event attributable to the intervention (e.g., persistent hyperglycemia, acute metabolic complications) * Patient refusal to continue the study or withdrawal of informed consent * Major non-adherence to the intervention (\<80% of planned intake or absence of isocaloric substitution) * Detection of a severe intercurrent condition requiring discontinuation of the intervention (e.g., heart failure decompensation, severe infection) * Loss to follow-up preventing the assessment of primary endpoints
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
La Rabta Hospital , Endocrinology Department
Tunis, 1, Tunisia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A special MRI peers into the chemistry of hearts and brains in diabetes
- Can pole walking boost heart fitness in diabetic patients?
- Can transplanted cells restore insulin production in type 2 diabetes?
- Could a common diabetes drug weaken or protect aging muscles?
- Gamifying exercise: could a phone app outperform traditional programs for obesity and diabetes?
- Can your DNA predict how you respond to a diabetes drug?